Dear Editor, We read the letter from Kapoor et al. [1] with interest. Their comments on antibiotics in general lack literature support. We emphasized the role of antibiotic exposure in ICU-acquired candidemia [2] . However, prior antibiotic use is not the only factor driving ICU-acquired candidemia. This is evidenced by the wide variation in preadmission exposure rates at the 27 centers: broad-spectrum antibiotics (62.5-100 %), carbapenems (0.0-84.6 %), and polymyxins (0.0-66.7 %). We also noted an inverse correlation between the candidemia burden and broad-spectrum antibiotic exposure (13 centers), carbapenems (10 centers) and polymyxins (7 centers).
Early onset of candidemia with lower APACHE II scores in Indian patients is not a matter of controversy but an observation of significance calling for appropriate and timely management of these patients. An informed physician would rely on indepth medical literature rather than cursory drug promotional literature for making therapeutic decisions. Our study at no point advocates indiscriminate, empirical use of antifungals. Instead our comprehensive analysis delineates admission to public sector hospitals, APACHE II scores, renal failure, central venous catheterization, steroid therapy, and susceptibility-based antifungal therapy as crucial factors influencing outcome. We highlighted that similar early onset candidemia has also been noted in some developed countries [2] . The precise reasons for such early onset candidemia are so far unknown, but could have a bearing on the complex dynamics of nosocomial infections including hand fungal carriage, hospital infection control, and invasive procedures.
The description of Kapoor et al. [1] regarding Indian ICUs also lacks evidence. No data are available on the number of ICU beds in public versus private hospitals in India. The closest estimates available for hospital beds show a 40:60 ratio for public versus private hospitals [3] . Crude estimates show 5-10 % beds dedicated to critical care in different hospitals with no distinction between the public and private sector [4] . Ironically, central India, where the lead author practices, has the lowest number of private hospital beds in the country [3] . Kapoor et al. [1] also make an incorrect claim about the Chennai Declaration's commitment to antifungal resistance. To date there have been no dedicated policies drafted by the Declaration for tackling antifungal resistance [5] . Lastly, the authors' estimates for the cost of echinocandins in India are grossly incorrect. Depending on the drug, current costs range from $100-450 (CIMS India; available from: http://www.mims. com/India).
However, we are in unison with Kapoor et al. in advocating antimicrobial and antifungal stewardship. We undertook this in-depth study to delineate the range of factors influencing ICU-acquired candidemia in India. Focusing solely on one factor cannot solve these challenges. Our study shows the need for a holistic approach giving due importance to all the factors involved.
